Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • stocklooking stocklooking Apr 12, 2013 2:48 AM Flag

    What were they doing these years?

    With 245 employees, a great platform, our own products are mostly in phase I or preclinical. In the mean time, TDM1 has already been approved. All are standing over there watching or lending hands to genetech scientists?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good question, many of us have been asking the same for the past year. I think 901 is older then T-DM1. I don't expect anything from 901, I think North will go South, but...if just one of the early stage, wholly owned drugs hits the mark (+ T-DM1 does $BB's), IMGN is cheap, if 2 hit, it's a triple even from here and if more than 2 hit IMGN could do what REGN did, CELG and many other big winners. We should learn more today.

 
IMGN
8.98-0.04(-0.44%)4:00 PMEDT